Parkinson's Disease 3 Medical, surgical, and physical treatments for Parkinson's disease

被引：1

作者：

Foltynie, Tom ^{[1
]}

Bruno, Veronica ^{[2
]}

Fox, Susan ^{[3
,4
]}

Kuehn, Andrea A. ^{[5
,6
,7
]}

Lindop, Fiona ^{[8
]}

Lees, Andrew J. ^{[1
,9
]}

机构：

[1] Natl Hosp Neurol & Neurosurg, UCL Inst Neurol, Dept Clin & Movement Neurosci, London WC1N 3BG, England

[2] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada

[3] Toronto Western Hosp, Krembil Brain Inst, Edmond J Safra Program Parkinson Dis, Toronto, ON, Canada

[4] Univ Toronto, Div Neurol, Toronto, ON, Canada

[5] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany

[6] Charite Univ Med Berlin, NeuroCure Cluster Excellence, Berlin, Germany

[7] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[8] Univ Hosp Derby & Burton NHS Fdn Trust, Florence Nightingale Community Hosp, Specialist Rehabil, Derby, England

[9] UCL, Reta Lila Weston Inst Neurol Studies, London, England

来源：

LANCET | 2024年 / 403卷 / 10423期

关键词：

DEEP-BRAIN-STIMULATION; SLEEP BEHAVIOR DISORDER; PLACEBO-CONTROLLED TRIAL; OXIDASE B INHIBITORS; DOUBLE-BLIND; SUBTHALAMIC NUCLEUS; MOTOR FLUCTUATIONS; OPEN-LABEL; SUBCUTANEOUS APOMORPHINE; SYMPTOMATIC TREATMENT;

D O I：

10.1016/S0140-6736(23)01429-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from a multidisciplinary team, and important new approaches in the delivery of dopamine replacement are becoming available. The more challenging, wide range of non-motor symptoms can also have a major impact on the quality of life of a patient with Parkinson's disease, and requires careful multidisciplinary management using evidence-based knowledge, as well as appropriately tailored strategies according to the individual patient's needs. Disease-modifying therapies are urgently needed to prevent the development of the most disabling refractory symptoms, including gait and balance difficulties, cognitive impairment and dementia, and speech and swallowing impairments. In the third paper in this Series, we present the latest evidence supporting the optimal treatment of Parkinson's disease, and describe an expert approach to many aspects of treatment choice where an evidence base is insufficient.

引用

页码：305 / 324

页数：20

共 213 条

[91] Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study [J].